HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

(R)- N- ((4- methoxy- 6- methyl- 2- oxo- 1,2- dihydropyridin- 3- yl)methyl)- 2- methyl- 1- (1- (1- (2,2,2- trifluoroethyl)piperidin- 4- yl)ethyl)- 1H- indole- 3- carboxamide

potent and selective histone methyltransferase EZH2 inhibitor; structure in first source

Also Known As:

CPI-1205

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide: 3

Experts

1.	Barazeghi, Elham: 1 article (11/2021)
2.	Hellman, Per: 1 article (11/2021)
3.	Norlén, Olov: 1 article (11/2021)
4.	Stålberg, Peter: 1 article (11/2021)
5.	Westin, Gunnar: 1 article (11/2021)
6.	Béguelin, Wendy: 1 article (01/2018)
7.	Giulino-Roth, Lisa: 1 article (01/2018)
8.	Gulati, Nitya: 1 article (01/2018)
9.	Albrecht, Brian K: 1 article (11/2016)
10.	Audia, James E: 1 article (11/2016)

Related Diseases

1.	Neoplasms (Cancer) 11/23/2021 - "Furthermore, EZH2 knockout inhibited tumor progression in a CNDT2.5 SI-NET xenograft mouse model, and treatment of SI-NET cell lines CNDT2.5 and GOT1 with the EZH2-specific inhibitor CPI-1205 decreased cell viability and promoted apoptosis. " 01/01/2018 - "Three EZH2 inhibitors: tazemetostat (EPZ-6438), GSK2816126 and CPI-1205 have moved into phase I/phase II clinical trials in patients with non-Hodgkin lymphoma and genetically defined solid tumors. "
2.	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/01/2018 - "Three EZH2 inhibitors: tazemetostat (EPZ-6438), GSK2816126 and CPI-1205 have moved into phase I/phase II clinical trials in patients with non-Hodgkin lymphoma and genetically defined solid tumors. "
3.	B-Cell Lymphoma (Lymphoma, B Cell) 11/10/2016 - "Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas."

Related Drugs and Biologics

1.	GSK-2816126
2.	tazemetostat
3.	Histone Methyltransferases